A gut hormone, ghrelin, is a key regulator of new nerve cells in the adult brain, a research team has discovered. It could help pave the way for new drugs to treat dementia in patients with Parkinson's Disease.
Can COVID-19 infection increase the risk of developing Parkinson's disease? That's the question posed by a new commentary that explores three known case studies of people developing Parkinson's-like symptoms in the weeks following infection with SARS-CoV-2.
New research shows a simple skin test can accurately identify Parkinson's disease, which could lead to earlier detection of the disease and better outcomes for patients. Currently, Parkinson's disease is diagnosed by clinical signs and symptoms but only definitively diagnosed at autopsy. The researchers conducted a blinded study of 50 skin samples using an assay originally designed to detect mad cow disease.
Researchers established an association between inflammation and specific genetic mutations in Parkinson's patients. The study highlights two biomarkers that could be used to assess Parkinson's disease state and progression. The results also suggest that targeting the immune system with anti-inflammatory medication holds the potential to influence the disease course, at least in a subset of patients.
A new database analysis of approximately 80,000 patients shows that people with Parkinson's disease (PD) have a 30 percent higher death rate from COVID-19 than people without the neurodegenerative condition.